Furthermore, in the RAINBOW trial, in which ramucirumab, a novel humanized monoclonal antibody VEGFR-2 antagonist, in combination with PTX, given as 2nd line chemotherapy, improved overall survival in 665 patients with advanced gastric cancer, ramucirumab was associated with a higher incidence of peripheral neuropathy of all grades than was PTX alone (46% vs. 37%) [14]. The gene discussed is KDR; the disease is gastric cancer.